TScan Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by TScan Therapeutics, Inc. on July 24, 2023, covering events reported on July 20, 2023. The Company is a biotechnology firm incorporated in Delaware, with its principal executive offices in Waltham, Massachusetts. The report focuses on significant changes to the Company's executive leadership team.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity metrics. This report is a current event disclosure and does not contain periodic financial statements.
Material Changes
The primary material change disclosed is the departure of Brian Silver as Chief Financial Officer and Principal Accounting Officer, effective July 21, 2023. Concurrently, the Board appointed two new officers effective July 21, 2023:
- Gavin MacBeath, Ph.D.: Appointed as Interim Principal Financial Officer. Dr. MacBeath has served as Chief Executive Officer since May 24, 2023.
- Leiden Dworak: Appointed as Principal Accounting Officer. Mr. Dworak previously served as Vice President, Finance since April 2022.
Compensatory Arrangements and Outlook
In connection with Mr. Dworak's appointment as Principal Accounting Officer, the Board approved the following compensatory adjustments:
- Base Salary Increase: Raised from $321,000 to $340,000.
- Target Annual Bonus: Increased from 30% to 35% of base salary.
- Stock Options: Awarded 25,000 shares of voting common stock with an exercise price of $2.23 per share (closing price on July 21, 2023).
- Vesting Schedule: Options vest over four years, with 25% vesting on the one-year anniversary and the remainder in 36 monthly installments, subject to continued employment.
The filing states there are no related party transactions requiring disclosure under Item 404(a) of Regulation S-K. No specific guidance, risks, or contingencies regarding future financial performance were disclosed in this document.
Investor Verification Checklist
- Verify the effective date of Brian Silver's resignation and the transition of duties to the interim CFO.
- Confirm the vesting terms and exercise price of the stock options granted to Leiden Dworak.
- Review subsequent filings for the appointment of a permanent Chief Financial Officer.
- Check for any related party transaction disclosures in future reports involving the new officers.